The question: Can we use a port system to deliver anti-VEGF for wet AMD instead of doing monthly injections?
In the LADDER trial (Long-Acting Delivery of Ranibizumab), they are testing long-term anti-VEGF delivery via a ranibizumab port delivery system (RPDS).
Tell me more about this port.
The RPDS is an implantable, refillable reservoir system that sits under the conjunctiva in the pars plana and is designed to gradually release ranibizumab (Lucentis). Here is a picture to help visualize that. The device requires a relatively simple surgical procedure to be implanted (done in the OR), and the port is refilled as an in-office procedure using a special needle.
Tell me about the study.
The Phase 2 trial included over 200 patients with wet AMD who previously had anti-VEGF injections. The study is using various concentrations of Lucentis for the port but the results have been promising. The researchers have found patients using the highest drug concentration were able to go a median of 15 months before needing a refill.
When could this become available?
Researchers anticipate if all goes well, 3 years. (via)
